Sessions

All Sessions
keyboard_arrow_down
filter_list Show filters Hide filters
  • All Tracks
  • The Great Hall
  • Aston Webb Reception
  • Elgar Concert Hall
  • G30
  • G31
The Great Hall
Conference & Exhibition Open
event_note Friday, 11 Oct 2019
query_builder 8:00 - 8:00
card_travel Exhibition
mic English
Conference & Exhibition Open
The Great Hall
Partnering Meetings
event_note Friday, 11 Oct 2019
query_builder 8:15 - 9:25
card_travel Partnering
mic English
Partnering Meetings
The Great Hall
Welcome
event_note Friday, 11 Oct 2019
query_builder 9:30 - 9:45
card_travel Keynote
mic English
Welcome
Speakers
John Harris
CEO
OBN (UK) Ltd
star star star star star
G31
BioLearn Masterclass: How the Drug Discovery Industry Works
event_note Friday, 11 Oct 2019
query_builder 9:45 - 10:15
card_travel BioLearn Masterclass
mic English
BioLearn Masterclass: How the Drug Discovery Industry Works
This Masterclass will cover a brief overview of the following topics in a small group training-session:
  • The commercial landscape
  • Human biology, pathology and drug targets
  • Drug discovery and development
  • Industry pressures and responses
  • Industry in transition
Speakers
Edward Zanders
Owner
PharmaGuide Ltd
star star star star star
Elgar Concert Hall
Panel: The Importance of Appointing & Retaining the Right Team & Board for your Organisation
event_note Friday, 11 Oct 2019
query_builder 9:45 - 10:30
card_travel Panel Discussion
mic English
Panel: The Importance of Appointing & Retaining the Right Team & Board for your Organisation
When pitching for investment the strength of the team is always given great importance, but how do you attract and most importantly retain the right talent for your organisation?

This panel will address the importance of factors such as promoting diversity, encouraging a healthier work/life balance, embracing flexible working, incentivisation (including EMI schemes), visa requirements for overseas staff, and creating a positive company culture for all staff. We will also address the importance of assembling an advisory board that provides balance to the skillset of your senior team, along with the benefits of collaborating with Big Pharma who can contribute skills and experience to your team and support growth for your business.   

Board recruitment, and more specifically, leveraging the right board members, should be among the most critical issues for any emerging company. The strength of an organisation and its ability to achieve its mission through smart governance, creative thinking, and fundraising is dependent on the board and those entrusted to lead it.

Critical board analysis should be employed to identify strengths of your current board but also identify gaps and the greatest areas of need. You may be surprised at what you find! Securing the right fit is vital for the health of your board and will impact your firm in myriad ways, not least overall organisational credibility which is crucial to securing investment from the financial markets.

Our expert panel will explain how to cultivate these relationships to ensure they bear fruit for years to come, as well as advice on:
  • Using relationships with current partners and friends of the organisation to help recruit new board members
  • Casting your net widely to unearth connections you didn’t know existed
  • Leveraging your networking activities to identify candidates
  • Defining and creating appropriate Roles and Responsibilities
  • How should board members be held accountable?
  • Dealing with disruptive board members
  • Being up front and transparent at the start of the relationship to avoid problems downstream
  • Recruiting a new board member provides the opportunity to hit the re-set button on the formalities around board standards
Speakers
Bryan Morton
Executive Chairman
EUSA Pharma
star star star star star
Paul Edwards
Managing Partner
Horton International Global Healthcare
star star star star star
Peter Dines
COO and Head of Life Sciences
Mercia Technologies
star star star star star
Samantha Westgate
CEO
Perfectus Biomed
star star star star star
Tobias Kloepper
CEO & Co-Founder
Aigenpulse Limited
star star star star star
G31
BioLearn Masterclass: Presentation Skills for Scientists
event_note Friday, 11 Oct 2019
query_builder 10:15 - 10:45
card_travel BioLearn Masterclass
mic English
BioLearn Masterclass: Presentation Skills for Scientists
This Masterclass will provide an overview the following topics in a small-group training session:
  • Nervousness and voice control
  • Verbal scientific delivery and communications
  • Slide content and quality
Speakers
Edward Zanders
Owner
PharmaGuide Ltd
star star star star star
Elgar Concert Hall
Panel: Going to America?
event_note Friday, 11 Oct 2019
query_builder 10:30 - 11:15
card_travel Panel Discussion
mic English
Panel: Going to America?
The US Healthcare market is valued at more than $2.8 Trillion and is frequently the number one priority for UK / Europe life sciences companies looking to expand their international presence and set up foreign subsidiaries. A US presence also facilitates the access to the US investment and capital markets, and the downstream opportunity to IPO via the Nasdaq equity market.

Whilst there are many similarities in business approach and language, there are also significant cultural and legal differences which can catch out the unwary when seeking to establish and operate a local entity.
Expanding into new markets, geographies, and market segments can be immensely rewarding but also challenging if approached without adequate preparation, knowledge and support. Companies need to think strategically about which avenues they need to explore to develop realistic market access strategies that create the opportunity for growth and long-term value creation.

Our expert panel will provide well informed advice as to how best to approach establishing a North American entity and develop practical strategies and plans to optimise operations, organisational structures, financials and processes across the life sciences value chain to maximise their chances of business success in this dynamic healthcare market.

Our panel will offer advice on the following topics:

Location
  • East, West, or Middle – are there areas more suitable for R&D or manufacturing operations?
  • Impact of time zones, access and travel
  • What are the varying incentives and taxation differences between States
Legal
  • FDA clearance and approval to obtain FDA certification
  • Risk management and insurance provisions to consider
  • Incorporation or branch legal structure?
  • Visas, relocation, tax, immigration issues
  • Differences in IP between the UK and US e.g. first to file vs first to invent
Business
  • Understanding how the health system works
  • Access to investment, capital, grants and where to leverage practical setup support
  • Tips on recruiting & retaining local staff
  • Identifying and interacting with a new range of US out-source partners
  • Local networking and interaction with the community
Speakers
Gary Baylis
Regulatory Adviser
REGISTRAR CORP USA
star star star star star
Charles Macdowell
Business Development Representative
VABeachBio
star star star star star
Huw Jones
CEO
Chronos Therapeutics
star star star star star
Nicholas Moore
Managing Director, Healthcare
Stifel
star star star star star
Joanne Farquharson
US Expansion Advisor & Global General Manager
Foothold America
star star star star star
'How To' Develop & Manage Your Corporate Reputation to Boost Value
event_note Friday, 11 Oct 2019
query_builder 11:15 - 12:15
card_travel 'How To'
mic English
'How To' Develop & Manage Your Corporate Reputation to Boost Value
A strong corporate reputation is a vital component of an organisation’s success, with financial analyst recommendations, CSR strategies, media exposure, industry collaborations and positive perceptions all helping to boost market value. Yet, many organisations ignore these aspects as they grapple with the more hard-edged, day-to-day urgencies – reputation is a long-term concept that is difficult to quantify.

One thing is certain, there is a high cost to pay for losing a good reputation and your good standing with stakeholders.  A smaller firm may be devastated by loss of reputation, so it pays to have a strategy in place outlining how you plan to build and manage your corporate reputation.

This ‘How To’ session will support you in doing just that, addressing the importance of positively promoting your organisation by highlighting your key assets; how to showcase your unique strengths when pitching for funding or entering into a collaboration, and the importance of understanding cultural communication differences when networking with investors and the wider industry. 

Our expert speakers will also cover:
  • Experience and information – how do others view you based on direct and indirect interaction?
  • Getting key stakeholders to perceive the company as credible, reliable, responsible and trustworthy
  • How do you develop a positive identity based on demonstrating consistent performance over a sustained period?
  • Leveraging stakeholder support for the firm in times of difficulty
  • Using reputation to generate sustained competitive advantage
  • The importance of key opinion leader endorsement
  • The role of social media in today's fast moving world
  • Managing your brand and ensure it is supported by stakeholder experience
  • In times of skill shortages, a good business reputation assists in employee recruitment, development and retention
  • Ethics – a firm that has an ethical reputation will engender positivity
Speakers
Sue Charles
Managing Partner
Instinctif
star star star star star
Kat Arney
Founder and Creative Director
First Create the Media Ltd
star star star star star
Chris Fisher
Partner
Instinctif
star star star star star
Sponsors
The Great Hall
Networking Break
event_note Friday, 11 Oct 2019
query_builder 11:15 - 11:30
card_travel Social
mic English
Networking Break
'How To' Successfully Prepare for a Company Exit
event_note Friday, 11 Oct 2019
query_builder 12:15 - 13:15
card_travel 'How To'
mic English
'How To' Successfully Prepare for a Company Exit
When it comes to preparing for a company exit, there is no universal answer.  Founders want to sell for as much money as possible (so do investors) and buyers want to spend as little as possible, so both parties need to find alignment.

Investors capitalise a company with one objective in mind: to get a return on their investment.

So, whilst Venture Capitalists, business angels and other types of investors may not look for an exit in the first few years of a start-up, they will require some type of liquidity event to put cash on the table. Exits provide capital to start-up investors, which can then return the money to their limited partners (in the case of Venture Capitalists) or to the investors themselves (in the case of business angels). If the return is sufficiently robust, this may encourage further investment in additional, early-stage Life Sciences companies.

This ‘How To’ session will explore this fascinating, and for most companies, commercially essential aspect of their corporate progression covering all stages of company development, whether they be start-ups or more mature companies with a transaction in their business plan.

Our experts will provide a practical ‘How To’ guide on:
  • When is the right time to exit?
  • Trade sales: A buyer takes over the start-up using cash or stock as a compensation
  • Floatation / IPO: A company floats on a stock market, selling a significant number of their shares in the process to institutional and non-institutional investors. IPO's can provide large sums of capital to all parties involved (founders, early employees and investors)
  • When and why do IPO’s make sense?
  • Which exchanges are likely to yield the best performance: NASDAQ, AIM, Euronext and other markets are potential vehicles for floatation
  • What happens post-IPO?
  • How do you progress from a VC/PE based environment to more institutional investors?
  • Mergers & Acquisitions: These transactions can imply a merging with a similar but larger company or a merger of equals to create increased critical mass. Public companies that have suffered a technology failure but still have development cash represent good reverse targets
  • How to go about it -  Is there a role for advisers?
  • Go to market: Companies that can establish a solid business model and scale might choose to stay independent and reinvest the profits in the company whilst avoiding the public markets and the obligations that come with it
Speakers
Keith Woodhouse
Partner
Fieldfisher LLP
star star star star star
Oliver Sexton
Investment Director
UKI2S
star star star star star
James Steel
Head of Healthcare
Peel Hunt LLP
star star star star star
Sponsors
Processing. Please wait.
Loading...